Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Antibody Therapeutics is Scopus-indexed (Q1, CiteScore 7.8), WoS ESCI, DOAJ. Published by Oxford University Press.
Checked against the index lists dated .
ISSN 2516-4236Verify ISSN ↗
Publisher: Oxford University Press
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Immunology and Allergy | 57 / 234 | 75th | Q1 |
| Immunology | 62 / 243 | 74th | Q2 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2018–present, best quartile Q1, CiteScore 7.8.
Antibody Therapeutics is Q1 in Immunology and Allergy (rank 57 of 234) and Q2 in Immunology (rank 62 of 243), by CiteScore 2025.
Antibody Therapeutics is indexed in the Emerging Sources Citation Index, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 7.8, which places it in quartile Q1 at the 75th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 1.003, quartile Q2, with an H-index of 30.
The publisher lists an article processing charge of about US$2,822 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Antibody Therapeutics is published by Oxford University Press. Its ISSN is 2516-4236.
Yes — indexed in the Emerging Sources Citation Index.
Yes — it is an open-access journal, listed in DOAJ.
Antibody Therapeutics has an h-index of 34 and a 2-year mean of 3.12 citations per paper (OpenAlex). Its Scopus CiteScore is 7.8, quartile Q1. On 2-year citations it ranks #79 of 231 Scopus journals in Immunology and Allergy.
Antibody Therapeutics published 28 papers in 2025; its busiest recent year was 2023 with 57. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 79 research articles (2024–2026), authors are most often from United States (42.6%), China (30.4%) and Japan (3.4%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.